Document AbbVie Inc. Guidance Including the Impact of Acquired IPR D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended
Tuesday, December 31, 2024 1 min read
Key Takeaway: AbbVie Inc. has updated its financial guidance for Q4 and full-year 2024, factoring in the impact of acquired IPR D and associated milestone expenses. The adjusted diluted EPS guidance suggests a decrease due to these costs, dropping lower than previous estimates. The firm projects an adjusted diluted EPS range of $2.06 to $2.10 for Q4 2024, down from its earlier guidance of $2.94 to $2.98. Despite these challenges, the company continues to provide comprehensive financial forecasts.
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie maintains adjusted diluted EPS guidance for Q4 and full-year 2024.
The inclusion of milestone expenses showcases the company's strategic planning.
CONCERNS & RISKS
The acquired IPR D and milestones expense negatively impacts earnings per share.
The adjustment reflects potential challenges in achieving previous profit expectations.
Full Press Release Details
Guidance Including the Impact of Acquired IPR D and Milestones Expense
(in millions, except per share data)
Quarter Ended December 31, 2024
Full-Year Ended December 31, 2024
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Acquired IPR D and Milestones Expense
Adjusted Diluted EPS Range
Low
High
Low
High
Previously announced guidance excluding Q4 2024 acquired IPR D and milestones expense
$
-
$
2.94
$
2.98
$
1,183
$
10.90
$
10.94
Q4 2024 acquired IPR D and milestones expense
1,574
(0.88)
(0.88)
1,574
(0.88)
(0.88)
Guidance including Q4 2024 Acquired IPR D and milestones expense
$
1,574
$
2.06
$
2.10
$
2,757
$
10.02
$
10.06
Frequently Asked Questions
What is the acquired IPR D and milestones expense for Q4 2024?
The acquired IPR D and milestones expense for Q4 2024 is $1,574 million.
What is the adjusted diluted EPS range for Q4 2024?
The adjusted diluted EPS range for Q4 2024 is $2.06 to $2.10.
What was the full-year acquired IPR D and milestones expense?
The full-year acquired IPR D and milestones expense was $2,757 million.
What is the adjusted diluted EPS for the full year 2024?
The adjusted diluted EPS for the full year 2024 ranges from $10.02 to $10.06.